Xencor (NASDAQ:XNCR) CEO Bassil Dahiyat Sells 6,758 Shares

Xencor, Inc. (NASDAQ:XNCR) CEO Bassil Dahiyat sold 6,758 shares of the firm’s stock in a transaction on Tuesday, March 3rd. The shares were sold at an average price of $11.90, for a total transaction of $80,420.20. Following the transaction, the chief executive officer owned 567,792 shares in the company, valued at $6,756,724.80. This represents a 1.18% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Xencor Stock Down 11.9%

NASDAQ:XNCR traded down $1.52 during trading hours on Thursday, reaching $11.22. The company’s stock had a trading volume of 824,452 shares, compared to its average volume of 683,552. The company has a debt-to-equity ratio of 0.12, a current ratio of 6.25 and a quick ratio of 6.25. The company has a market cap of $822.86 million, a price-to-earnings ratio of -9.05 and a beta of 0.95. Xencor, Inc. has a one year low of $6.92 and a one year high of $18.69. The business’s 50-day moving average is $12.96 and its 200-day moving average is $12.91.

Xencor (NASDAQ:XNCR) last announced its quarterly earnings results on Wednesday, February 25th. The biopharmaceutical company reported ($0.09) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.64) by $0.55. The company had revenue of $28.24 million during the quarter, compared to analysts’ expectations of $29.97 million. Xencor had a negative return on equity of 14.58% and a negative net margin of 73.20%.The business’s quarterly revenue was down 46.6% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.62) earnings per share. Equities research analysts predict that Xencor, Inc. will post -3.68 EPS for the current year.

Analyst Ratings Changes

A number of equities analysts have recently commented on the stock. Barclays lifted their price target on shares of Xencor from $26.00 to $27.00 and gave the company an “overweight” rating in a research report on Thursday, February 26th. Wedbush reiterated an “outperform” rating and issued a $26.00 target price on shares of Xencor in a report on Thursday, November 6th. JPMorgan Chase & Co. cut their target price on shares of Xencor from $20.00 to $18.00 and set an “overweight” rating for the company in a research report on Thursday, November 6th. Wall Street Zen downgraded Xencor from a “hold” rating to a “sell” rating in a research report on Saturday, February 28th. Finally, Cantor Fitzgerald lifted their price objective on Xencor from $40.00 to $42.00 and gave the stock an “overweight” rating in a research note on Thursday, November 6th. Eight equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $25.00.

Institutional Investors Weigh In On Xencor

Institutional investors have recently added to or reduced their stakes in the company. Hantz Financial Services Inc. raised its holdings in Xencor by 209.1% in the 3rd quarter. Hantz Financial Services Inc. now owns 3,187 shares of the biopharmaceutical company’s stock valued at $37,000 after acquiring an additional 2,156 shares in the last quarter. GAMMA Investing LLC lifted its position in Xencor by 77.1% in the third quarter. GAMMA Investing LLC now owns 3,328 shares of the biopharmaceutical company’s stock worth $39,000 after purchasing an additional 1,449 shares during the period. Farther Finance Advisors LLC acquired a new stake in Xencor during the third quarter worth $44,000. Tower Research Capital LLC TRC increased its holdings in Xencor by 118.4% in the 2nd quarter. Tower Research Capital LLC TRC now owns 5,568 shares of the biopharmaceutical company’s stock valued at $44,000 after buying an additional 3,018 shares during the period. Finally, Federated Hermes Inc. raised its stake in shares of Xencor by 114.3% in the 3rd quarter. Federated Hermes Inc. now owns 3,947 shares of the biopharmaceutical company’s stock valued at $46,000 after buying an additional 2,105 shares in the last quarter.

Xencor Company Profile

Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor’s research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.

The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.